We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UK’s NICE Rejects Bristol-Myers Squibb’s Multiple Sclerosis Drug
UK’s NICE Rejects Bristol-Myers Squibb’s Multiple Sclerosis Drug
The UK’s National Institute for Health and Care Excellence (NICE) has rejected Bristol Myers Squibb’s multiple sclerosis (MS) drug Zeposia (ozanimod) for use by the National Health Service over cost concerns.